Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study

Oliver J. Gurney-Champion*, Eva Versteijne, Astrid van der Horst, Eelco Lens, Heidi Ruetten, Hanne D. Heerkens, Gabriel M. R. M. Paardekooper, Maaike Berbee, Coen R. N. Rasch, Jaap Stoker, Marc R. W. Engelbrecht, Marcel van Herk, Aart J. Nederveen, Remy Klaassen, Hanneke W. M. van Laarhoven, Geertjan van Tienhoven, Arjan Bel

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: To assess the effect of additional magnetic resonance imaging (MRI) alongside the planning computed tomography (CT) scan on target volume delineation in pancreatic cancer patients.Material and methods: Eight observers (radiation oncologists) from six institutions delineated the gross tumor volume (GTV) on 3DCT, and internal GTV (iGTV) on 4DCT of four pancreatic cancer patients, while MRI was available in a second window (CT+MRI). Variations in volume, generalized conformity index (CIgen), and overall observer variation, expressed as standard deviation (SD) of the distances between delineated surfaces, were analyzed. CIgen is a measure of overlap of the delineated iGTVs (1=full overlap, 0=no overlap). Results were compared with those from an earlier study that assessed the interobserver variation by the same observers on the same patients on CT without MRI (CT-only).Results: The maximum ratios between delineated volumes within a patient were 6.1 and 22.4 for the GTV (3DCT) and iGTV (4DCT), respectively. The average (root-mean-square) overall observer variations were SD=0.41cm (GTV) and SD=0.73cm (iGTV). The mean CIgen was 0.36 for GTV and 0.37 for iGTV. When compared to the iGTV delineated on CT-only, the mean volumes of the iGTV on CT+MRI were significantly smaller (32%, Wilcoxon signed-rank, p

Original languageEnglish
Pages (from-to)923-930
Number of pages8
JournalActa Oncologica
Volume56
Issue number7
DOIs
Publication statusPublished - 2017

Keywords

  • TARGET VOLUME DELINEATION
  • RADIATION-THERAPY
  • INTRATUMORAL FIDUCIALS
  • OBSERVER VARIATION
  • QUALITY-ASSURANCE
  • CANCER ANALYSIS
  • SCALOP TRIAL
  • RADIOTHERAPY
  • VARIABILITY
  • MARKERS

Cite this